Here's Why Every Marijuana Investor Should Learn About Beta-Glucan

The medical marijuana market is expected to double in size by 2020 as clinical studies provide evidence that cannabis can safely be used as an alternative medicine. GW Pharma (GWPH) and PharmaCyte (PMCB), for example, are driving development of new cannabinoid drug candidates for serious diseases, including epilepsy and cancer, as potential alternatives to chemotherapy and other standards of care that are known to cause serious adverse events.

ImmuDyne (OTC: IMMD) is leveraging its proprietary beta-glucan ("β-glucan"), a natural immune-modulator derived from baker's yeast, to develop and market products that safely enhance the body's immune system and potentially combat disease. Beta-glucan is exempt as a drug by the FDA under a classification known as 'Generally Regarded As Safe' (GRAS). This allows IMMD to sell its β-glucan derived products directly to consumers and bypass the FDA's expensive drug development process. Beta-glucan is considered a nutraceutical not a drug.

Like medical marijuana...

Rate this article: 
Region: 

This marijuana news is brought to you by 420 Intel. For the latest breaking cannabis industry news, subscribe to the 420 Intel newsletter. If you'd like to promote your product or service in this area after every article, contact us.